Chemotherapy and Radiation for Pancreatic Cancer Before Surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Pancreatic cancer confirmed by biopsy that is resectable or borderline resectable with high-risk factors (CA19-9 > 200, tumor > 2 cm, or advanced lymph node involvement)
- No previous chemotherapy, radiation, immunotherapy, or other cancer treatments
- Good overall health status (ECOG 0–1) with life expectancy ≥ 3 months
- Normal blood counts, liver, kidney, and heart function (specific lab values required)
- Not pregnant and willing to use contraception during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial compares adding radiation to chemotherapy versus chemotherapy alone after surgery for pancreatic cancer. It is for people whose cancer had certain high-risk features found during surgery, and who have not yet started additional treatment.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial tests a short course of radiation combined with chemo and the immunotherapy drug camrelizumab before surgery for pancreatic cancer. It aims to shrink tumor to make removal easier and improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.